Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from PRISM BioLab Co. LTD ( (JP:206A) ) is now available.
PRISM BioLab Co., Ltd. announced the termination of its Collaboration & License Option Agreement with Servier, which was initially aimed at identifying compounds for a challenging drug target. Despite successful joint research outcomes, including insights into compound structures, the companies decided to end the collaboration due to shifting business priorities. The termination will not affect PRISM’s financial results, and the company plans to leverage the research data for future partnerships.
More about PRISM BioLab Co. LTD
PRISM BioLab Co., Ltd. operates in the biotechnology industry, focusing on the discovery and development of novel compounds for drug targets. The company collaborates with pharmaceutical entities to advance research and development in challenging areas of drug discovery.
Average Trading Volume: 173,475
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen6.44B
For detailed information about 206A stock, go to TipRanks’ Stock Analysis page.